PharmaVentures Podcast Series, Edition 3
Review of 2022: M&A, Licensing and Fundraising
Hosted by Adrian Dawkes
Listen as Fintan Walton, PharmaVentures’ CEO and Founder, reflects on this year’s deal trends in M&A, Licensing and Fundraising, considers the significant macroeconomic events, and offers insight into what impact they may have on the global pharma and biotech industry in 2023.
Review of 2022: M&A, Licensing and FundraisingDownload Request
If you would prefer to read the transcript of the podcast please email: firstname.lastname@example.org
About the Presenter:
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
About the Interviewee:
Fintan Walton is the Founder and CEO of PharmaVentures.
Over a period of three decades, he has built it into a global player in supporting transactions for blue chip corporations and emerging innovator corporations. In that time, the firm has delivered more than 1,000 transaction related assignments for companies in 38 countries.
Dr Walton majored in Genetics at Trinity College Dublin, Ireland, where he also gained a Ph.D. Prior to his entrepreneurial activities at PharmaVentures, Fintan had built his R&D and commercial experience in biotechnology within management positions at Bass and Celltech plc (1982-1992). In 1996, he also founded PharmaDeals, the leading database and publishing business related to deal making data and analytics, which was sold to IMS Health (now IQVIA) in 2012.